Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANV419 First-in-Human Study in Advanced Solid Tumors
NCT04855929Phase 1Completed
- Sponsor
- Anaveon
- Start
- May 2021
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of ANV419 in solid tumor (advanced stage) and lung cancer (2 arms), sponsored by Anaveon. Primary endpoints: Number of Dose-Limiting Toxicities (DLTs) - Monotherapy, Number of Dose-Limiting Toxicities (DLTs) - Combination and 2 more. Started May 2021; status: completed.
02
Drugs
ANV419
03
Conditions
solid tumor (advanced stage)lung cancer
Beyond the preview
Go deeper on NCT04855929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855929.